Skip to main content

Table 1 mRECIST criteria

From: Assessment of the relationship between hepatocellular carcinoma location and its response to transarterial chemoembolization

Complete response (CR) Disappearance of any intratumoral arterial enhancement in all target lesions
Partial response (PR) At least a 30% decrease in the sum of diameters of viable target lesions
Stable disease (SD) Any cases that do not qualify for either partial response or progressive disease
Progressive disease (PD) Increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions